Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for removal of viruses from blood by lectin affinity hemodialysis

a technology of lectin affinity hemodialysis and virus removal, which is applied in the direction of anti-noxious agents, drug compositions, other blood circulation devices, etc., can solve the problems of limiting the effectiveness of therapy, compromising the immune response of the infected individual, and the immune system being unable to defend against opportunistic infections, etc., to achieve the effect of reducing viral load

Inactive Publication Date: 2007-09-20
AETHLON MEDICAL INC
View PDF41 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is a method for reducing the viral load in infected blood or plasma using lectins that bind to pathogens with high mannose glycoproteins. The method involves immobilizing lectin molecules on a porous hollow fiber membrane and then passing the blood or plasma through the membrane. This results in the lectins binding to the viral particles or fragments, reducing the viral load in the effluent. The method can be used to treat infections, such as HIV and hepatitis C, simultaneously. The invention provides an apparatus comprising hollow fibers with immobilized lectins for this purpose."

Problems solved by technology

In cases where drug treatments are available, the occurrence of resistant mutations and drug side effects often limit the effectiveness of therapy.
It infects selected cells of the immune system thereby compromising the infected individual's immune response.
The hallmark of AIDS is the gradual loss of CD4+ T cells, which ultimately leaves the immune system unable to defend against opportunistic infections.
Currently there is no cure for HIV infection.
While more than 16 drugs and drug combinations have been approved by the FDA for treating HIV infection, the emergence of drug resistant mutants and the presence of the untreatable virus reservoirs (e.g. in memory T cells) has limited their usefulness.
Unfortunately, no effective HIV vaccine has been forthcoming due, in part, to the rapid mutation of the HIV genome and the inaccessibility of immunogenic epitopes of viral proteins.
They do not directly remove HIV virus.
However, none of these treatments effectively remove both virus and viral proteins.
However, none of these chromatographic materials are selective for viruses and will clearly remove many other essential substances.
Thus they are not usefull for in vivo blood purification.
However, this strategy was inefficient as it required extracorporeal absorption of blood and did not provide for a mechanism to remove free HIV viral particles from the blood (Lopukhin et al., 1991, supra).
Accordingly, although lectins are known to bind viral envelope glycoproteins, no previous technologies have been developed using lectins to directly adsorb HIV or other enveloped viruses from the blood using in vivo dialysis or plasmapheresis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for removal of viruses from blood by lectin affinity hemodialysis
  • Method for removal of viruses from blood by lectin affinity hemodialysis
  • Method for removal of viruses from blood by lectin affinity hemodialysis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0038] This Example demonstrates the preparation of an affinity matrix using GNA covalently coupled to Agarose using Cyanogen Bromide. Cyanogen bromide (CNBr) activated agarose was used for direct coupling essentially according to Cuatrecasas, et al (Cuatracasas et al. Proc Natl Acad Sci USA 61(2): 636-643, 1968). In brief, 1 ml of GNA at a concentration of 10 mg / ml in 0.1M NaHCO3 pH 9.5 is added to 1 ml CNBr activated agarose (Sigma, St. Louis, Mo.) and allowed to react overnight in the cold. When the reaction is complete, unreacted materials are aspirated and the lectin coupled agarose washed extensively with sterile cold PBS. The lectin agarose affinity matrix is then stored cold until ready for use. Alternatively, GNA agarose is available commercially from Vector Labs (Burlingame, Calif.).

example 2

[0039] This Example demonstrates preparation of the lectin affinity matrix using GNA covalently coupled to glass beads via Schiff's base and reduction with cyanoborohydride. The silica lectin affinity matrix was prepared by a modification of the method of Hermanson (Hermanson. Bioconjugate Techniques: 785, 1996). GNA lectin was dissolved to a final protein concentration of 10 mg / ml in 0.1M sodium borate pH 9.5 and added to aldehyde derivatized silica glass beads (BioConnexant, Austin Tex.). The reaction is most efficient at alkaline pH but will go at pH 7-9 and is normally done at a 2-4 fold excess of GNA over coupling sites. To this mixture was added 10 μl 5M NaCNBH3 in 1N NaOH (Aldrich, St Louis, Mo.) per ml of coupling reaction and the mixture allowed to react for 2 hours at room temperature. At the end of the reaction, remaining unreacted aldehyde on the glass surfaces are capped with 20 μl 3M ethanolamine pH 9.5 per ml of reaction. After 15 minutes at room temperature, the reac...

example 3

[0040] This Example demonstrates preparation of GNA covalently coupled to aminocelite using glutaraldehyde. Aminocelite was prepared by reaction of celite (silicate containing diatomaceous earth) by overnight reaction in a 5% aqueous solution of aminopropyl triethoxysilane. The aminated celite was washed free of excess reagent with water and ethanol and dried overnight to yield an off white powder. One gram of the powder was then suspended in 5 ml 5% glutaraldehyde (Sigma) for 30 minutes. Excess glutaraldehyde was then removed by filtration and washing with water until no detectable aldehyde remained in the wash using Schiff's reagent. The filter cake was then resuspended in 5 ml of Sigma borohydride coupling buffer containing 2-3 mg / ml GNA and the reaction allowed to proceed overnight at room temperature. At the end of the reaction, unreacted GNA was washed off and the unreacted aldehyde aminated with ethanolamine as described. After final washing in sterile PBS, the material was s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual.

Description

[0001] This application is a continuation of U.S. patent application Ser. No. 10 / 760,810, filed Jan. 20, 2004, which claims the benefit under 35 USC §119(e) of U.S. Provisional Application No. 60 / 440,771, filed Jan. 17, 2003, the disclosures of which are incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates to the field of therapeutic methodologies for treating viral infections. BACKGROUND OF THE INVENTION [0003] A large number of viruses have been described which are pathogenic for humans. Among these viruses are many for which neither drugs nor vaccines are available. In cases where drug treatments are available, the occurrence of resistant mutations and drug side effects often limit the effectiveness of therapy. Examples of such viruses include Hepatitis C and human immunodeficiency virus (HIV). [0004] HIV is the etiological agent of acquired immunodeficiency syndrome (AIDS). It infects selected cells of the immune system thereby compromisin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/70A61BA61K35/14A61L2/02A61M1/14A61M1/34A61M1/38A61M37/00
CPCA61L2/02A61M1/3486A61M1/3472A61L2/022A61P31/12A61P31/18A61P39/00
Inventor TULLIS, RICHARD H.
Owner AETHLON MEDICAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com